Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 987M 865M 797M 746M 1.4B 93.06B 1.43B 9.58B 3.71B 45.99B 3.7B 3.62B 159B P/E 2026 *
-6.54x
P/E 2027 * -6.04x
Enterprise Value 877M 769M 709M 664M 1.24B 82.75B 1.27B 8.52B 3.3B 40.9B 3.29B 3.22B 142B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.74%
1 week+12.25%
Current month+12.78%
1 month+12.78%
3 months-20.98%
6 months+15.52%
Current year+16.50%
1 week 8.84
Extreme 8.84
9.99
1 month 7.32
Extreme 7.315
9.99
Current year 7.23
Extreme 7.23
14.25
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
26.7
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2018
Director of Finance/CFO 52 31/08/2019
Chief Tech/Sci/R&D Officer - 17/08/2025
Director TitleAgeSince
Chairman 68 06/03/2018
Director/Board Member 47 06/05/2018
Director/Board Member 62 31/01/2020
Date Insider Type Main position Quantity % Market Cap.
02-23Fiscal year

Chief Financial Officer

156,000 0.1602%
01-15Sell

Founder

6,700 0.0069%
01-01Free

Chief Executive Officer

787,500 0.8086%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%+12.25%-7.57%+19.27% 987M
+0.33%+1.37%+63.66%+123.67% 55.63B
+0.82%+15.05%+79.52%+88.67% 52.25B
+1.36%+0.36%-14.52%-14.67% 23.07B
-1.04%+7.91%+3.91%+413.05% 22.41B
+6.72%+14.64%+37.39%-1.97% 17.32B
-1.10%+4.00%+29.97%-32.75% 15.94B
+2.89%+5.51%+25.42%+188.41% 13.77B
-3.35%+8.96%+134.32%+282.61% 13.47B
+5.69%+12.39%+34.78% - 12.43B
Average +1.28%+5.52%+38.69%+118.48% 22.73B
Weighted average by Cap. +1.02%+5.16%+49.10%+122.38%

Financials

2026 *2027 *
Net sales - -
Net income -155M -136M -126M -118M -221M -14.67B -225M -1.51B -584M -7.25B -584M -571M -25.13B -186M -163M -150M -141M -264M -17.53B -269M -1.81B -699M -8.67B -698M -683M -30.05B
Net Debt -109M -95.86M -88.36M -82.72M -155M -10.31B -158M -1.06B -411M -5.1B -411M -402M -17.67B -231M -203M -187M -175M -328M -21.82B -335M -2.25B -870M -10.79B -869M -850M -37.4B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
104
Date Price Change Volume
26/06/26 US$9.530 +0.74% 3,762,524
25/06/26 US$9.460 +0.32% 1,646,575
24/06/26 US$9.430 +5.84% 1,707,947
23/06/26 US$8.910 -0.22% 1,181,179
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
9.530USD
Average target price
20.29USD
Spread / Average Target
+112.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock